科研成果详情

题名Pan-Cancer Analysis Predicts FOXS1 as a Key Target in Prognosis and Tumor Immunotherapy
作者
发表日期2022
发表期刊INTERNATIONAL JOURNAL OF GENERAL MEDICINE   影响因子和分区
语种英语
原始文献类型Article
关键词FOXS1 pan-cancer biological marker M2-like macrophages Treg cells immunosuppressive microenvironment
其他关键词FORKHEAD ; PROGRESSION
摘要Purpose: Only a few studies have reported the role of FOXS1, a transcriptional factor, in the tumor development process. In this article, we investigate the function of FOXS1 in distinct neoplastic development and the tumor immune microenvironment (TIME). Patients and Methods: The latent roles of FOXS1 in various tumors were prospected based on TCGA, GTEx, CCLE, GEPIA2, cBioPortal, TIMER, ImmuCellAI databases, GSVA datasets, GSEA datasets, and R packages. The expression difference, gene alteration, clinical characteristics, prognostic values, biological mechanism, potential pathways, tumor microenvironment, and immune cell infiltration related to FOXS1 were appraised. Results: FOXS1 was strongly expressed in pan-cancer, and this gene was associated with low survival rates. FOXS1 was linked to many pathways that are cancer-promoting and immune-related. The expression of this transcriptional factor in cancers was positively related to immune cell infiltration, especially M2-like macrophages and Treg cells. In addition to that, FOXS1 demonstrated a positive relationship with many immune-suppression genes, such as TGFB1 and ARORA2A. Conclusion: Our study identified an oncogenic effect of FOXS1, which may play a vital role as a prognosticative biological marker in pan-cancer. Exorbitant expression of FOXS1 is associated with high TAMs and Treg cells infiltration. These cells have an immunosuppressive function and promote the development of the immunosuppressive tumor microenvironment. The research of FOXS1 provided a potential drug target for tumor immunotherapy.
出版者DOVE MEDICAL PRESS LTD
出版地ALBANY
ISSN1178-7074
EISSN1178-7074
卷号15页码:2171-2185
DOI10.2147/IJGM.S354195
页数15
WOS类目Medicine, General & Internal
WOS研究方向General & Internal Medicine
WOS记录号WOS:000764009900005
收录类别SCIE ; PUBMED ; SCOPUS
URL查看原文
PubMed ID35241932
PMC记录号PMC8887970
SCOPUSEID2-s2.0-85125226900
通讯作者地址[Wang, Lingling]Department of Clinical Laboratory Center of the Second Affiliated Hospital & Yu Ying Children’s Hospital of Wenzhou Medical University,Zhejiang Province,Wenzhou,325027,China
Scopus学科分类Medicine (all)
引用统计
被引频次:2[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符https://kms.wmu.edu.cn/handle/3ETUA0LF/5193
专题眼视光学院(生物医学工程学院)、附属眼视光医院
检验医学院(生命科学学院、生物学实验教学中心)
附属第二医院
第二临床医学院、附属第二医院、育英儿童医院
通讯作者Wang, Lingling
作者单位
1.School of Medical College,Guangdong Medical University,Guang Dong Province,Zhanjiang,524023,China;
2.Eye Hospital and School of Ophthalmology and Optometry,Wenzhou Medical University,Zhejiang Province,Wenzhou,325027,China;
3.National Clinical Research Center for Ocular Diseases,Zhejiang Province,Wenzhou,325027,China;
4.Department of Clinical Laboratory Center of the Second Affiliated Hospital & Yu Ying Children’s Hospital of Wenzhou Medical University,Zhejiang Province,Wenzhou,325027,China;
5.School of Laboratory Medicine and Life Sciences,Wenzhou Medical University,Zhejiang Province,Wenzhou,325035,China
通讯作者单位附属第二医院
推荐引用方式
GB/T 7714
Liu, Yunqiang,Tu, Mengjun,Wang, Lingling. Pan-Cancer Analysis Predicts FOXS1 as a Key Target in Prognosis and Tumor Immunotherapy[J]. INTERNATIONAL JOURNAL OF GENERAL MEDICINE,2022,15:2171-2185.
APA Liu, Yunqiang, Tu, Mengjun, & Wang, Lingling. (2022). Pan-Cancer Analysis Predicts FOXS1 as a Key Target in Prognosis and Tumor Immunotherapy. INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 15, 2171-2185.
MLA Liu, Yunqiang,et al."Pan-Cancer Analysis Predicts FOXS1 as a Key Target in Prognosis and Tumor Immunotherapy".INTERNATIONAL JOURNAL OF GENERAL MEDICINE 15(2022):2171-2185.

条目包含的文件

条目无相关文件。
个性服务
查看访问统计
谷歌学术
谷歌学术中相似的文章
[Liu, Yunqiang]的文章
[Tu, Mengjun]的文章
[Wang, Lingling]的文章
百度学术
百度学术中相似的文章
[Liu, Yunqiang]的文章
[Tu, Mengjun]的文章
[Wang, Lingling]的文章
必应学术
必应学术中相似的文章
[Liu, Yunqiang]的文章
[Tu, Mengjun]的文章
[Wang, Lingling]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。